No pain, still gain

OXFORD - British Biotech plc last week successfully concluded with almost no pain two of the legal difficulties arising from its dispute with Andrew Millar, its former director of clinical research, over the conduct of its clinical program.

The company (LSE:BBG; BBIOY, Oxford, U.K.) settled its legal battle with Millar, who was seeking compensation for wrongful dismissal after having been fired for alleged breach of contract (see BioCentury, May 20, 1998). Then the U.S. Securities Exchange Commission completed its investigation of claims that BBG had made overly optimistic statements in press releases about the development of its marimastat cancer treatment...